Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases

By Jialiang Hu, P. Steen, Q. Sang, G. Opdenakker. Nature reviews. Drug discovery, 2007

786 citations recorded by the source corpus.

Subfields: Cancer Research, Hematology, Oncology

View Paper: https://www.semanticscholar.org/paper/22e1442f1d3934f52d2d22c4964f57ba3763c2d3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. R. Khalil
2. Gillian Murphy
3. Xi Wang
4. Hideaki Nagase
5. P. E. Van den Steen
6. J. Vandooren
7. G. Opdenakker
8. A. Nurden

In Hematology

1. Gillian Murphy
2. Hideaki Nagase
3. Xi Wang
4. R. Khalil
5. J. Vandooren
6. G. Opdenakker
7. P. E. Van den Steen

In Oncology

1. R. Khalil
2. Xi Wang
3. Hideaki Nagase
4. Gillian Murphy
5. J. Vandooren
6. G. Opdenakker
7. P. E. Van den Steen

Citations in the corpus

• Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. (2008, background): “injectables that target tumor necrosis factor-α (TNF- α) as effective anti-inflammatory agents (118, 119).”
• Progress in matrix metalloproteinase research. (2008, background): “Such studies have reiterated the observation that the relevance of MMP expression profiles varies with the nature of the cells, the stage of the disease and the genetic make up of the animal (Hu et al., 2007; Lemaitre and D’Armiento, 2006; Martin and Matrisian, 2007).”
• Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. (2018, background): “Tetracyclines such as doxycycline and mechanism-based MMP inhibitors such as SB-3CT also inhibit MMPs by chelating Zn2+ (Hu et al., 2007).”
• Matrix metalloproteinases. (2010, background): “Future investigations on specific pathways, their interactions with metal binding proteins and protein action inhibition diversify their study to include research areas in a variety of academic disciplines [205-209].”
• Platelets, inflammation and tissue regeneration (2011, background): “Other situations where MMPs can be active pathogenic agents include lung fibrosis (reviewed in [87]).”
• Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade (2013, background): “A valuable overview of Mmp KO phenotypes, with for each study information about the genetic background is available (Hu et al., 2007).”